Axovant Sciences is dedicated to delivering novel therapeutic solutions to patients living with dementia today Axovant Sciences, AXON (NYSE) a majority-owned subsidiary of Roivant, is a clinical-stage biopharmaceutical company dedicated to comprehensively addressing the cognitive, behavioral, and functional components of dementia.
Axovant Sciences, Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”AXON” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/axovant” connections=”true” suffix=””]
July 2018, Axovant licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy. Axovant will pay Benitec an upfront payment of $10 million for rights to the AXO-AAV-OPMD program and five additional investigational gene therapy products, as well as payments tied to development, regulatory and commercial sales milestones.
In June 2018, Axovant licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica an investigational gene therapy for Parkinsons disease as well as its predecessor product ProSavinë.
In Nov 2015, Axovant Sciences Ltd. received an option to acquired exclusive, worldwide to develop and commercialize nelotanserin from Axovants majority owner, Roivant Sciences Ltd.
In Jun 2015, Axovant Sciences raised approx. $360 Mn USD through IPO listing to fund Phase III clinical studies of RVT-101.